Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Raltegravir PK in Neonates—Modeling Rising and Declining PK Profiles of Newborns Exposed to Raltegravir In Utero
Raltegravir PK in Neonates—An Adaptive Trial Design to Define an Appropriate Regimen for Neonates from Birth to 6 Weeks of Age
A PK/PD Model-based Meta-analysis of Subcutaneously Administered Insulins in Clinical Glucose Clamp Studies
In this webinar, we discussed a population pharmacokinetic modeling and simulation approach to design a raltegravir dosing regimen for the prevention or treatment of HIV in newborns up to 6 weeks of age.